TELA Bio misses Q2 revenue estimates

TELA Bio

11/08/2025 21:11

Overview

TELA Bio Q2 revenue rises 26% yr/yr but misses analyst expectations, per LSEG data

Net loss for Q2 narrows to $9.92 mln from $12.6 mln a year earlier

Co reiterates 2025 revenue growth guidance of 23% to 27% yr/yr

Outlook

Company reiterates 2025 revenue guidance of $85 mln to $88 mln

TELA Bio projects 23% to 27% revenue growth for 2025

Company focuses on enhanced territory management for growth

TELA Bio expands European market presence with new product launch

Result Drivers

PRODUCT DEMAND - Increased demand for OviTex and OviTex PRS products drove revenue growth, per CEO Antony Koblish

NEW CUSTOMERS - Revenue growth attributed to new customer acquisitions and international sales expansion

PRODUCT MIX - Decrease in average selling prices due to shift towards smaller-sized units

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Revenue
Miss
$20.20 mln
$20.70 mln (5 Analysts)
Q2 Net Income
-$9.92 mln
Q2 Basic EPS
-$0.22
Q2 Gross Profit
$14.10 mln
Q2 Income From Operations
-$9.08 mln
Q2 Operating Expenses
$23.19 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"

Wall Street's median 12-month price target for TELA Bio Inc is $6.00, about 71.3% above its August 8 closing price of $1.72

Press Release: ID:nGNXbs7zt8

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)